326 related articles for article (PubMed ID: 17309568)
1. Apheresis in coronary heart disease with elevated Lp (a): a review of Lp (a) as a risk factor and its management.
Keller C
Ther Apher Dial; 2007 Feb; 11(1):2-8. PubMed ID: 17309568
[TBL] [Abstract][Full Text] [Related]
2. LDL apheresis: a novel technique (LIPOCOLLECT 200).
Stefanutti C; Di Giacomo S; Mazzarella B; Castelli A
Artif Organs; 2009 Dec; 33(12):1103-8. PubMed ID: 19995360
[TBL] [Abstract][Full Text] [Related]
3. Lipoprotein Lp(a) excess and coronary heart disease.
Stein JH; Rosenson RS
Arch Intern Med; 1997 Jun; 157(11):1170-6. PubMed ID: 9183227
[TBL] [Abstract][Full Text] [Related]
4. Comparison of different Lp (a) elimination techniques: a retrospective evaluation.
Borberg H
Transfus Apher Sci; 2009 Aug; 41(1):61-5. PubMed ID: 19540812
[TBL] [Abstract][Full Text] [Related]
5. Is lipoprotein (a)-apheresis useful?
Bambauer R
Ther Apher Dial; 2005 Apr; 9(2):142-7. PubMed ID: 15828926
[TBL] [Abstract][Full Text] [Related]
6. Dramatic fate of a young coronary heart disease patient rescued with specific lipoprotein(a) apheresis.
Safarova MS; Ezhov MV; Afanasieva OI; Konovalov GA; Pokrovsky SN
J Clin Apher; 2015 Jun; 30(3):193-5. PubMed ID: 25181645
[TBL] [Abstract][Full Text] [Related]
7. LDL-apheresis: indications and clinical experience in a tertiary cardiac centre.
Archontakis S; Pottle A; Hakim N; Ilsley C; Barbir M
Int J Clin Pract; 2007 Nov; 61(11):1834-42. PubMed ID: 17935547
[TBL] [Abstract][Full Text] [Related]
8. Specific Lp(a) apheresis: A tool to prove lipoprotein(a) atherogenicity.
Pokrovsky SN; Afanasieva OI; Safarova MS; Balakhonova TV; Matchin YG; Adamova IYU; Konovalov GA; Ezhov MV
Atheroscler Suppl; 2017 Nov; 30():166-173. PubMed ID: 29096833
[TBL] [Abstract][Full Text] [Related]
9. The importance of Lp(a)-fibronectin interaction in atherogenesis.
Sönmez H; Süer S; Kökoğlu E; Dirican A; Ulutin T; Uçişik N; Ulutin ON
Haematologia (Budap); 1997; 28(3):149-53. PubMed ID: 9283915
[TBL] [Abstract][Full Text] [Related]
10. [Lipoprotein (a)--a mysterious factor in atherogenesis].
Jelaković B; Laganović M; Kuzmanić D
Lijec Vjesn; 2002; 124(11-12):366-71. PubMed ID: 12679978
[TBL] [Abstract][Full Text] [Related]
11. Plasma lipoprotein Lp(a), markers of haemostasis and inflammation, and risk and severity of coronary heart disease.
Imhof A; Rothenbacher D; Khuseyinova N; Hoffmeister A; Maerz W; Nauck M; Scharnagl H; Koenig W; Brenner H
Eur J Cardiovasc Prev Rehabil; 2003 Oct; 10(5):362-70. PubMed ID: 14663298
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of LDL-apheresis in preventing restenosis after percutaneous transluminal coronary angioplasty (PTCA): LDL-apheresis angioplasty restenosis trial (L-ART).
Yamaguchi H; Lee YJ; Daida H; Yokoi H; Miyano H; Kanoh T; Ishiwata S; Kato K; Nishikawa H; Takatsu F
Chem Phys Lipids; 1994 Jan; 67-68():399-403. PubMed ID: 8187240
[TBL] [Abstract][Full Text] [Related]
13. Impact of markedly elevated serum lipoprotein(a) levels (> or = 100 mg/dL) on the risk of coronary heart disease.
Murase T; Okubo M; Amemiya-Kudo M; Hiraga T; Oka J; Shimada M; Igarashi T
Metabolism; 2007 Sep; 56(9):1187-91. PubMed ID: 17697860
[TBL] [Abstract][Full Text] [Related]
14. Impact of elevated serum lipoprotein (a) concentrations on the risk of coronary heart disease in patients with type 2 diabetes mellitus.
Murase T; Okubo M; Amemiya-Kudo M; Ebara T; Mori Y
Metabolism; 2008 Jun; 57(6):791-5. PubMed ID: 18502261
[TBL] [Abstract][Full Text] [Related]
15. Extracorporeal immunoadsorption for the specific removal of lipoprotein (a) (Lp(a) apheresis): preliminary clinical data.
Pokrovsky SN; Sussekov AV; Afanasieva OI; Adamova IY; Lyakishev AA; Kukharchuk VV
Chem Phys Lipids; 1994 Jan; 67-68():323-30. PubMed ID: 8187230
[TBL] [Abstract][Full Text] [Related]
16. [Specific Lp(a) apheresis for secondary prevention of arteriosclerosis].
Ullrich H; Matic BG; Lackner KJ; Rothe G; Schmitz G
Beitr Infusionsther Transfusionsmed; 1997; 34():248-55. PubMed ID: 9417344
[TBL] [Abstract][Full Text] [Related]
17. Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels.
Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Hohenstein B; Roeseler E; Heigl F; Grützmacher P; Blume H; Klingel R; Vogt A;
Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):33-38. PubMed ID: 30838552
[TBL] [Abstract][Full Text] [Related]
18. Lipoprotein(a)-apheresis in the secondary prevention of coronary heart disease.
Ullrich H; Lackner K; Schmitz G
Transfus Sci; 1996 Dec; 17(4):511-7. PubMed ID: 10168548
[TBL] [Abstract][Full Text] [Related]
19. Lipoprotein(a)-apheresis in the light of new drug developments.
Vogt A
Atheroscler Suppl; 2017 Nov; 30():38-43. PubMed ID: 29096859
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany.
Heigl F; Hettich R; Lotz N; Reeg H; Pflederer T; Osterkorn D; Osterkorn K; Klingel R
Atheroscler Suppl; 2015 May; 18():154-62. PubMed ID: 25936320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
